Mukka Proteins Ltd Stock Hits All-Time Low Amidst Prolonged Downtrend

Stock Performance Overview

The share price of Mukka Proteins Ltd has been on a downward trajectory, falling by 0.69% on the latest trading day, slightly worse than the Sensex’s marginal decline of 0.09%. Over the past six consecutive trading days, the stock has lost 4.07% in value. This recent slump culminated in the stock hitting ₹23.02, its lowest level ever recorded.

When compared to broader market indices, the stock’s performance has been notably weak. Over one week, Mukka Proteins declined by 3.78% versus the Sensex’s 1.93% fall. The one-month return stands at -6.69%, significantly underperforming the Sensex’s -0.66%. The disparity widens over longer periods: a three-month loss of 12.37% contrasts with a 2.36% gain in the Sensex, while the one-year return is a steep -38.37% against the Sensex’s positive 8.36%.

Longer-term figures reveal a stagnant performance, with zero returns over three, five, and ten years, while the Sensex has delivered 38.45%, 72.41%, and 237.32% respectively over the same periods. Year-to-date, the stock has declined 3.54%, lagging behind the Sensex’s 1.31% fall.

Technical indicators also signal weakness, as Mukka Proteins is trading below all key moving averages: 5-day, 20-day, 50-day, 100-day, and 200-day. This suggests a sustained bearish trend without signs of immediate recovery.

Financial Metrics and Profitability

Mukka Proteins’ financial health presents several concerns. The company’s average Return on Capital Employed (ROCE) stands at 9.16%, indicating limited profitability relative to the capital invested. This figure is considered low within the FMCG sector, where efficient capital utilisation is critical for sustainable growth.

Debt servicing capacity is another area of caution. The company’s Debt to EBITDA ratio is elevated at 5.26 times, reflecting a high level of leverage relative to earnings before interest, tax, depreciation, and amortisation. This ratio suggests a constrained ability to meet debt obligations comfortably.

Net sales growth has been modest, with an annualised increase of 8.60% over the past five years. While this indicates some expansion, it is relatively subdued compared to sector peers and broader market expectations.

Recent Quarterly Results

The company has reported negative results for seven consecutive quarters, underscoring ongoing financial pressures. Profit Before Tax excluding Other Income (PBT less OI) for the latest quarter was ₹3.28 crores, a sharp decline of 67.9% compared to the average of the previous four quarters. Similarly, Profit After Tax (PAT) dropped by 45.9% to ₹5.88 crores in the same period.

Interest expenses have reached a peak, with ₹12.82 crores recorded in the latest quarter, further impacting net profitability and cash flow.

Institutional Investor Activity

Institutional investors have reduced their holdings by 0.6% in the previous quarter, now collectively owning 3.36% of the company’s shares. This decline in institutional participation may reflect a reassessment of the company’s fundamentals by investors with greater analytical resources.

Comparative Sector and Market Context

In contrast to Mukka Proteins’ performance, the FMCG sector and broader market indices have generally shown resilience. The Sensex’s positive returns over one year and three months highlight the stock’s relative underperformance. Additionally, the company’s market capitalisation grade is rated 4, indicating a smaller market cap relative to peers, which may contribute to liquidity and valuation challenges.

Valuation and Growth Considerations

Despite the challenges, Mukka Proteins exhibits some positive attributes. Operating profit has grown at an annual rate of 50.86%, signalling operational improvements in certain areas. The company’s Enterprise Value to Capital Employed ratio is 1.3, suggesting a valuation discount compared to historical averages of its peers.

However, the stock’s Mojo Score remains low at 31.0, with a current Mojo Grade of Sell, downgraded from Strong Sell on 14 Nov 2025. This reflects a cautious stance based on comprehensive financial and market data.

Summary of Key Challenges

The stock’s decline to an all-time low is underpinned by a combination of factors: subdued sales growth, low capital efficiency, high leverage, and a series of negative quarterly results. The elevated interest burden and reduced institutional ownership further compound the situation. These elements have contributed to the stock’s underperformance relative to the Sensex and FMCG sector benchmarks over multiple time horizons.

While operating profit growth has been robust, it has not translated into improved bottom-line results or market valuation. The company’s valuation discount relative to peers reflects market caution amid these financial metrics.

Market Capitalisation and Trading Context

Mukka Proteins’ market capitalisation grade of 4 indicates a relatively small market cap, which may affect trading volumes and investor attention. The stock’s consistent trading below all major moving averages signals a lack of upward momentum in the near term.

Day-to-day price movements have been in line with the FMCG sector, but the cumulative effect over weeks and months has been a marked decline, emphasising the stock’s current position at a historic low.

Conclusion

The fall of Mukka Proteins Ltd to its lowest-ever price level on 09 Jan 2026 is a significant event reflecting ongoing financial and market pressures. The company’s performance metrics, including profitability, leverage, and investor participation, highlight the severity of the current situation. While some operational metrics show growth, these have not yet translated into improved financial outcomes or market confidence.

Investors and market participants will continue to monitor the stock’s trajectory within the context of the FMCG sector and broader market conditions.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →